Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Menarini Group
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.
The European cancer congress returns in-person, with companies big and small presenting new agents and combinations across tumor types.
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing